Based on the search results, I can see that Kyverna Therapeutics is a late-stage biotech company developing CAR-T cell therapies for autoimmune diseases. Their lead candidate miv-cel has shown strong data in stiff person syndrome (SPS) and they are advancing a rolling BLA submission for FDA approval, expected to complete in Q4 2026. They also have ongoing registrational trials in myasthenia gravis. The Q3 2026 earnings are scheduled for November 11, 2026 (tomorrow).

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Kyverna typically reports earnings after market close, meaning Day 0 reflects anticipation before results are released, while Day +1 captures the market's first full reaction to the report.

Kyverna's post-earnings price action has been relatively muted on the day of the report but more volatile in the following session. Over the past eight quarters, the stock has moved an average of 3.24% on Day 0, with a typical intraday range of 7.13%. Day +1 shows significantly more movement, with an average absolute move of 7.83% and a range of 12.83%.

The most dramatic reactions came in Q3 2025 and Q1 2025, when Day +1 moves reached -11.60% and +14.90%, respectively, with ranges exceeding 13%. More recent quarters have shown tighter action—Q2 2026 saw a modest +5.38% Day +1 move, while Q3 2026 (August 2026) was relatively quiet with a +1.65% Day 0 move and just +0.37% on Day +1.

The pattern suggests that initial reactions are often subdued, with investors digesting the results overnight before making larger positioning decisions the following day. Given the company's current focus on regulatory milestones rather than clinical data releases at earnings, recent volatility has been lower than in earlier periods when trial results drove larger swings.

Part 2.2: Options Market Expected Move

The options market is pricing a 9.37% expected move for the November 20 expiration, which is slightly above the stock's average Day 0 move of 3.24% but below the average Day +1 move of 7.83%. The expected move is also lower than the average combined two-day range of 12.83%, suggesting options traders are anticipating a more moderate reaction than the stock has historically delivered following earnings.

Part 3: What Analysts Are Saying

Analysts are overwhelmingly bullish on Kyverna, with 6 Strong Buys, 0 Moderate Buys, 1 Hold, and no Sell ratings, translating to an average recommendation of 4.71 out of 5.0. The consensus price target of $30.40 implies 498% upside from the current price of $5.08, with individual targets ranging from a low of $25.00 to a high of $33.00.

The sentiment has remained unchanged over the past month, with the same 4.71 average recommendation and no shifts in the distribution of ratings. This stability reflects analyst confidence in the company's execution on its BLA submission and clinical trial progress, even as the stock has declined significantly from earlier levels.

The bullish consensus is driven by miv-cel's potential to become the first approved CAR T-cell therapy for autoimmune disease, addressing a large unmet need in stiff person syndrome (a rare disease with no approved therapies) and generalized myasthenia gravis (a $6.7 billion market opportunity by 2032). Analysts view the December 2025 topline data from the KYSA-8 trial as transformative, with statistically significant improvements across all endpoints and a favorable safety profile that could support outpatient administration.

The wide gap between the current price and analyst targets reflects both the high-risk, high-reward nature of clinical-stage biotech and the market's discounting of execution risk, regulatory uncertainty, and the need for additional capital. However, the unanimous Strong Buy consensus and lack of any bearish ratings underscore the Street's conviction that Kyverna's clinical data and regulatory pathway position it as a compelling opportunity at current levels.

Part 4: Technical Picture

The Barchart Technical Opinion for Kyverna is a 100% Sell signal, unchanged from both last week and last month, indicating sustained bearish momentum. The signal has been at maximum strength throughout this period, reflecting consistent technical weakness.

Timeframe Analysis:

• Short-term (100% Sell): Maximum sell signal indicates severe near-term downward pressure and negative momentum
• Medium-term (100% Sell): Continued sell signal across the intermediate timeframe suggests no relief in the downtrend
• Long-term (100% Sell): Persistent sell signal in the longer-term view reflects entrenched weakness across all time horizons

The trend is characterized by Maximum strength and is Strengthening, indicating that bearish technical conditions are not only severe but intensifying heading into the earnings release. This creates a challenging technical backdrop for the report, as the stock would need a significant catalyst to reverse the entrenched downtrend.

The stock is trading at $5.08, which is above the 5-day moving average of $4.98 but below every other key moving average: the 10-day ($5.27), 20-day ($5.49), 50-day ($6.42), 100-day ($7.30), and 200-day ($7.94). This configuration—where the stock sits below all major intermediate and long-term moving averages—is a classic bearish setup, indicating a sustained downtrend with lower highs and lower lows over the past several months.

The stock has declined 36% from its 200-day moving average, reflecting significant technical damage. The only positive is the recent bounce above the 5-day average, suggesting a potential short-term stabilization. However, with resistance at every moving average level above and maximum sell signals across all timeframes, the technical setup heading into earnings is decidedly unfavorable. Any positive surprise from the earnings report—particularly updates on BLA submission progress or cash runway—would need to be substantial to overcome this deeply oversold technical picture and trigger a meaningful reversal.